Tanya Ridding’s Post

EndoQuest Robotics™ has announced that it has received FDA investigational device exemption (IDE) approval for a study of its surgical robot. This exemption permits the Houston-based company to assess the performance and safety of its Endoluminal Surgical (ELS) system in colorectal surgery. The pivotal, multi-centre, open-label study will evaluate the ELS system in robotic endoscopic submucosal dissection (ESD) procedures for the removal of colorectal lesions. EndoQuest anticipates the participation of 50 subjects in the study, which will be conducted at five top U.S. healthcare institutions: Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). EndoQuest raised $42 million to support the platform a year ago. “This IDE approval marks a significant milestone in EndoQuest’s mission to revolutionize minimally invasive surgery. Our flexible robotic technology has the potential to transform colorectal surgical outcomes, empowering physicians with innovative tools to deliver less invasive, scar-free procedures,” said Eduardo F., interim CEO of EndoQuest Robotics. “We’re excited to proceed to human cases and move one step closer to initiating the next paradigm of surgery.” #SurgicalRobotics #Endoscopy #MedTech

Medtronic expects to submit its Hugo surgical robot to the FDA for urology indications in early 2025. This is a significant milestone in their journey to revolutionize surgical robotics. Chair and CEO Geoff Martha emphasized that this submission is just the beginning, with continued investments and developments in the pipeline. On a recent earnings call, Martha highlighted Medtronic's commitment to securing a strong foundation for future growth. Alongside the Hugo submission, they've launched initiatives like Touch Surgery Live Stream and achieved rapid enrollment in hernia and gynecology studies. Keeping innovation at the forefront, Medtronic also plans to integrate new technologies like ICG fluorescent imaging and LigaSure vessel-sealing into Hugo by 2025. This aligns perfectly with their lofty long-term goal of leading the surgical robotics industry, not just participating. #MedTech #SurgicalRobotics #Innovation

I shared yesterday that Medtronic have been dominating the headlines in recent days and today they are back with another significant story. Fortimedix Surgical B.V. Surgical announced today that it has been acquired by Medtronic. The company aims to set a new standard for robotic and non-robotic endoscopic therapeutic intervention and minimally invasive surgery. The proprietary technology offers utility in endoscopic therapeutic interventions and minimally invasive surgery, enabling early-stage surgical intervention endoscopically, otherwise known as endoluminal surgery. I referenced yesterday that Geoff Martha outlined the plan to pursue acquisitions like this one, saying the company targets tuck-in acquisitions with a “top-down approach.” Naturally, this has significant implications for Medtronic's Hugo robot play and adds further spotlight on the company. Congrats at this stage to Wout Bijker and the entire Fortimedix Surgical team.

🚨 From MassDevice: Medtronic’s Hugo Surgical Robot: FDA Submission on the Horizon 🚨 At R2 Surgical, we closely monitor developments in surgical robotics—our bread and butter is providing high-quality pre-owned solutions like the da Vinci Si and Xi systems, trusted by surgeons worldwide. So, when a major competitor makes moves, we take note. Medtronic has announced plans to submit its Hugo surgical robot for FDA approval for urology procedures in early 2025. While Hugo has been positioned as a challenger to the long-dominant da Vinci platform, its journey to market leadership has been slow. Medtronic’s strategy includes investing in the platform’s foundation, expanding indications to areas like hernia and gynecology, and integrating tech like ICG fluorescent imaging and LigaSure vessel-sealing. With more data in hand and new leadership in robotic surgery, Medtronic is signaling commitment. R2 is proud to support hospitals and surgical teams worldwide with flexible, cost-effective access to proven robotic technology. It’ll be interesting to see how the Hugo platform evolves in this competitive landscape. What’s your take on Medtronic’s push into robotic surgery? Let’s discuss! Read the full article here: https://lnkd.in/g4PhEVFj #SurgicalRobotics #DaVinci #MedtronicHugo #InnovationInHealthcare

“Percutaneous intervention has the opportunity to dramatically increase the treatment options for the millions of people suffering from heart valve disease. At Capstan, we believe that our robotic platform with a full portfolio of implants can uniquely address the urgent needs of this underserved patient population,” CEO Maggie Nixon said in a statement. That potentially includes patients whose anatomy may preclude them from other minimally invasive treatment approaches or whose risks may be too high to undergo open surgery, the company said.

We’re only 2 weeks away from #GRSS2024, CMR Surgical’s free virtual event presented in partnership with Surgery International. Join us to connect with the global surgical community and engage in key conversations with over 30+ leading experts and more than 800 delegates.    Over two days, you’ll hear from insightful panels on current topics impacting surgical robotics:    🔎 Truth or hype: Does AI/digital bring value to the OR? 🔎 Standardisation - Are we really ready to train our future robotic surgeons? 🔎 Why are we still debating lap vs surgical robotics?  🔎 Is robotic surgery really a luxury?   In addition to panel sessions, join registrants for a series of specialty focused interactive evidence-based robotic workshops across:    ✅ Urology ✅ Head and Neck  ✅ Colorectal ✅ Thoracic  ✅ Gynaecology  ✅ General Surgery    You don’t want to miss out on this free and accessible opportunity to engage with the global surgical community, register here: https://lnkd.in/eGfFK3ic  

Johnson & Johnson MedTech's FDA approval to begin clinical trials for the #Ottava surgical robot is a promising leap in surgical innovation. By integrating robotic arms directly into the operating table and supporting multiple surgical modalities, Ottava has the potential to redefine surgical precision and efficiency. This initiative underscores J&J's dedication to advancing the science of #surgery for better patient outcomes worldwide. #SurgicalInnovation #MedTech #RoboticSurgery #HealthcareAdvancement

Ellie Urenko '25 pitched Intuitive Surgical Inc. (NASDAQ: ISRG) on October 28, 2024. Intuitive Surgical designs, manufactures, and markets robotic surgical systems aimed at enhancing clinical outcomes through minimally invasive procedures. Intuitive has placed over 9,500 da Vinci Surgical Systems in 71 countries, facilitating over 14.2 million procedures. The company holds a dominant market share and is a global leader in the robotic-assisted surgery space. Intuitive continuously innovates its da Vinci system and has expanded its offerings beyond surgery to include the Ion Endoluminal System, a robotic-assisted, catheter-based platform for minimally invasive biopsies of the lung. Ellie's investment thesis highlighted the increasing adoption of robotic-assisted surgery, driven by its proven benefits of enhanced precision, dexterity, and efficiency, which result in fewer complications and shorter hospital stays. During the company's third quarter earnings call, it projected 17% year-over year revenue growth, expecting this trend to continue in 2025, driven by the full release of the da Vinci 5 Surgical System. Due to the Intuitive Surgical stock currently trading at an all time high, SMIF decided to track the performance of Intuitive for the remainder of the semester.

🌟 Transforming Vision Care in Singapore: SERI Partners with Carl Zeiss Meditec The Singapore Eye Research Institute (SERI) and Carl Zeiss Meditec have announced a major collaboration, OPTIZS (Ophthalmic Tech Innovation by ZEISS and SERI), with a combined investment of SG$20 million over three years. This partnership aims to revolutionize cataract and refractive surgery by: 👁️ Optimizing cataract surgery outcomes for faster recovery and long-term stability 👁️ Addressing presbyopia and refractive errors to meet the needs of Singapore’s aging population 🔗Discover how this partnership is shaping the future of vision care here: https://lnkd.in/djpbjNtp #Innovation #Collaboration #Cataract #VisionCare